Page 1,201«..1020..1,2001,2011,2021,203..1,2101,220..»

Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation – Business Wire

Posted: January 5, 2020 at 3:44 am

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced the pricing of the sale of 2,383,090 shares of common stock of OncoCyte Corporation at a price to buyers of $2.156 per share, representing the average closing price of OncoCyte common stock over the five trading days prior to the execution of the agreement. Net proceeds from the sale were approximately $5 million. The sale is expected to close by January 9, 2020, subject to certain closing conditions. Following the completion of the sale, Lineage will own approximately 6 million shares, which represents less than 10% of OncoCytes outstanding common stock. Based on the closing price of OncoCytes common stock on January 2, 2020, the value of Lineages remaining OncoCyte shares following the closing is approximately $13.5 million. Lineage has agreed not to sell additional shares of OncoCyte common stock until March 17, 2020 or unless the OncoCyte common stock price closes above $3.40.

Lineage is working diligently to become a leading cell therapy company and usher in a new branch of medicine, based on transplanting intact and differentiated cells into the body to restore activity lost to aging, injury, or disease, stated Brian M, Culley, CEO. To support our mission, we have deployed a financial strategy featuring intelligent cost-cutting alongside selectively selling our investments in OncoCyte and AgeX, companies which originated at Lineage prior to becoming independent public entities. Notably, we believe this most recent transaction involving OncoCyte will enable Lineage to have sufficient capital to support our core programs and will bridge us to the $21.6 million promissory note due to us in August 2020 from Juvenescence Ltd. Assuming the Juvenescence note is paid in cash and on time, we believe Lineages 2020 budget is now fully-funded and our available cash will extend well into 2021. Moving forward, we will continue to strategically assess and leverage all of the funding mechanisms at our disposal, including our remaining investments and potential partnership opportunities to support the development of our OpRegen, OPC1 and VAC2 programs, each of which may represent billion-dollar market opportunities in the emerging fields of cell therapy and immuno-oncology.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineages programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineages clinical assets include (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. Lineage is also evaluating potential partnership opportunities for Renevia, a facial aesthetics product that was recently granted a Conformit Europenne (CE) Mark. For more information, please visit http://www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as believe, may, will, estimate, continue, anticipate, design, intend, expect, could, plan, potential, predict, seek, should, would, contemplate, project, target, tend to, or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the timing and closing of Lineages sale of OncoCytes shares and Lineages planned spending for the year ending December 31, 2020. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineages actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineages business and other risks in Lineages filings with the Securities and Exchange Commission (the SEC). Lineages forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading Risk Factors in Lineages periodic reports with the SEC, including Lineages Annual Report on Form 10-K filed with the SEC on March 14, 2019 and its other reports, which are available from the SECs website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

More:
Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation - Business Wire

Posted in Cell Therapy | Comments Off on Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation – Business Wire

Global CAR-T Cell Therapy Market 2020 Opportunity Assessment, Analysis, Size, Share and Forecast Report to 2025 – Instanews247

Posted: January 5, 2020 at 3:44 am

The Global CAR-T Cell Therapy Market covers important aspects of this market concerning fundamental parameters. The report explains outline of the business range, concentrating on the overall industry, development possibilities, types and application. It brief CAR-T Cell Therapy summary of the market considering the current and future scenarios. It also provides information in terms of development and its capacities.

The CAR-T Cell Therapy industry analysis size, share, growth, trends, and forecasts 20202025. The CAR-T Cell Therapy report help to analysis players to improve their business strategies and helpful data. It shows key players in the worldwide market and trends about methodologies utilizing to separate themselves from other players. The analysis involves a broad outline of the CAR-T Cell Therapy market information on different particular divisions. The CAR-T Cell Therapy research report gives a pestal analysis rely upon the total market, available size, development scene, and analysis.

Detailed TOC along with also Charts and Tables of CAR-T Cell Therapy Market Research Report accessible at: https://www.futuristicreports.com/request-sample/29684

Sorrento Therapeutics Inc., Legend Biotech (Genscript Biotech Corporation), Kite Pharma Inc. (Gilead Sciences Inc.), Pfizer Inc., Novartis International AG, Celgene Corporation, Mustang Bio Inc., CARsgen Therapeutics Ltd., Aurora Biopharma Inc

This CAR-T Cell Therapy report explores feasibility with an objective of educational new entrants in regards to the changes within the market. The description, thorough SWOT analysis & investment analysis is given which CAR-T Cell Therapy predictions are impending opportunities for its players.

Geographically, global CAR-T Cell Therapy market report offers segment research and export and import status, require status, production volume, including regions such as North America, South America, Europe, China, Japan, India, The Middle East & Africa, Others.

Get it in Discounted Price: https://www.futuristicreports.com/check-discount/29684

The CAR-T Cell Therapy market gives fundamental data about the significant difficulties that will impact on development. Furthermore gives in general insights concerning the business. The report will help the current market to inspect the different aspects on growing their business.

It provides in-depth study on the current state of the global CAR-T Cell Therapy industry with focused growth. The report provides key statistics. The report provides an in-depth insight of 2020-2025 global CAR-T Cell Therapy covering all important parameters.

Enquire more at: https://www.futuristicreports.com/send-an-enquiry/29684

Company Name: Futuristic Reports

Email: [emailprotected]

Visit our website: https://www.futuristicreports.com

Phone: +1 (408) 520 9037

Address: 2066 N. Capitol Ave, Suite 3041

City: San Jose, CA 95132

Country: United States

Go here to see the original:
Global CAR-T Cell Therapy Market 2020 Opportunity Assessment, Analysis, Size, Share and Forecast Report to 2025 - Instanews247

Posted in Cell Therapy | Comments Off on Global CAR-T Cell Therapy Market 2020 Opportunity Assessment, Analysis, Size, Share and Forecast Report to 2025 – Instanews247

Top 10 ALS Stories of 2019 – ALS News Today

Posted: January 5, 2020 at 3:44 am

Throughout 2019, ALS News Today brought you daily coverage of key findings, treatment developments, clinical trials, and other events related to amyotrophic lateral sclerosis (ALS).

As a reminder of what mattered most to you in 2019, here are the top 10 most-read articles of last year with a brief description of what made them interesting and relevant to the ALS community.

We look forward to reporting more news to patients, family members, and caregivers dealing with ALS during 2020.

No. 10 Experimental Gene Therapy Successfully Silences Key ALS Gene C9orf72, Preclinical Studies Show

A tale of two preclinical studies showed that a gene therapy candidate targeting a key ALS mutation in the C9orf72 gene was able to lessen the buildup of toxic RNA clumps and reduce the activity of the mutated gene in cells collected from a patient with frontotemporal dementia (FTD) and a mouse model of ALS.

Developed by uniQure,the therapy is designed to silence thedisease-causing gene. It works by delivering microRNAs (miRNAs) RNA molecules that regulate gene expression that target the mutated C9orf72s RNA for degradation. The results supported the continuation of uniQures gene therapy program in ALS and FTD, the company said.

No. 9 Altered Gut Microbiota in ALS Patients Could Drive Digestive Problems, Study Suggests

In the summer, a small study discovered an altered composition of gut microbes in people with ALS, which could drive digestive problems in those with the disease.

Using genetics, a research team in China found that fecal samples of people with ALS have an increase in harmful microbes of the phylum Firmicutes and a decrease in beneficial microorganisms called Bacteroidetes. The resulting poor gastrointestinal health may lead to a decline in the guts digestion and metabolism functions.

No. 8 Ibudilast-Rilutek Therapy Combo Closer to U.S. Patent for ALS and Other Neurodegenerative Diseases

At the beginning of the year, U.S. biopharmaceutical MediciNova received a notice of allowance stating that its request for a patent covering a combination of its investigational therapy ibudilast (MN-166) plus Rilutek (riluzole) was being consideredby the U.S. Patent and Trademark Office.

Ibudilast is a small molecule that reduces the activity of immune cells in the brain while supporting the growth of motor neurons, those lost in people with ALS. In a Phase 2 trial (NCT02238626), the treatment was found to work well in combination with Sanofis approved therapy Rilutek, improving patients functional activity, quality of life, and muscle strength.

The notice of allowance was the final step toward patent registration. Such registration will provide patent protection until November 2035 to the combination, for use in treating ALS and other neurodegenerative diseases.

No. 7 MediciNova Launches Phase 2b/3 Trial of Ibudilast for ALS

In June, MediciNova launched a Phase 2b/3 clinical trial to continue studying ibudilast as an add-on therapy to Rilutek. The multicenter, double-blind study (NCT04057898) will recruit approximately 230 participants, who will be randomly selected to receive either ibudilast plus Rilutek or a placebo plus Rilutek for 12 months.

The trials main goal is to study ibudilasts impact on ALS progression and functional disability by determining changes in the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score between the beginning and end of the treatment period. Secondary objectives include changes in patients muscle strength, quality of life, and respiratory function. The study also will evaluate the safety and tolerability profile of ibudilast.

No. 6 FDA Approves Pivotal Phase 2b/3 Trial for Ibudilast in ALS Patients

Just a few months earlier, MediciNova had received approval from the U.S. Food and Drug Administration (FDA) to initiate this trial. Eligible patients must have had the disease for no more than 18 months and present just mild disability.

During the trial, patients will receive Rilutekfor at least 30 days before starting a regimen of either 100 mg per day of ibudilast or a placebo for a period of 12 months. Participants may then enter an extension phase in which they will be offered the ibudilast combination for an additional six months. Top-line data is expected by December 2021.

No. 5 Phase 3 Trial of NurOwn Cell Therapy Fully Enrolls 200 Patients, BrainStorm Announces

The Phase 3 trial evaluatingBrainStorm Cell Therapeuticss cell therapy candidateNurOwn completed patient enrollment in October. The 200 participants will receive three administrations of NurOwn, or a placebo, into the spinal canal every two months. The primary goals are to demonstrate the therapys safety and its ability to slow disease progression.

A cell-based therapy, NurOwn works by removing specific stem cells from patients and converting them to cells that produce molecules that promote nerve tissue growth and survival. The modified cells are then returned to the patient to stimulate nerve tissue growth. NurOwn aims to safely improve abilities like swallowing, speech, handwriting, and walking in people with ALS.

No. 4 High-dose Vitamin B12 May Improve ALS Prognosis if Started Early, Study Suggests

A long-term Phase 2/3 study examining vitamin B12 as a treatment for ALS found that ultra-high doses of methylcobalamin, the physiologically active form of this vitamin, may extend survival and slow the decline in functional capacity, compared with a placebo.

The study included 373 patients, diagnosed fewer than three years earlier, across 51 sites in Japan. However, the benefits were only seen in patients diagnosed less than one year before taking the supplements, and only a trend was observed.

No. 3 CuATSM Therapy May Slow ALS Progression, Improving Cognition and Respiration in Patients, Phase 1 Trial Shows

Results from a Phase 1 clinical trial (NCT02870634) showed that CuATSM a small molecule able to selectively deliver copper to cells with damaged mitochondria slowed disease progression and improved the respiratory and cognitive function of people with ALS.

Damaged mitochondria are considered a hallmark of several neurodegenerative diseases, including ALS, and delivering copper is thought to restore the health of these organelles. Developer Collaborative Medicinal Development (CMD) began testing CuATSM in patients with sporadic and familial ALS in 2016.CMD is now planning to launch a randomized, placebo-controlled clinical trial for CuATSM to confirm these results.

No. 2 Bacteria and Fungi Found in Central Nervous System of ALS Patients, Study Reports

In March, a study discovered several species of bacteria and fungi living in the central nervous system (CNS) of people with ALS, suggesting that patients have coexisting bacterial and fungal infections.

The study built on prior research suggesting that ALS might be caused by a fungal infection. Researchers then examined frozen CNS tissue from 11 ALS patients to assess whether bacterial infections accompany fungal infections. Bacterial DNA was found in different regions of the CNS and the presence of bacteria was confirmed in neural tissue samples.

No. 1 Nerve Injury May Trigger Onset, Progression of ALS Symptoms, Rat Study Suggests

Our most-read article of 2019reported that small nerve damage may serve as an ALS trigger. Such damage may accelerate motor symptoms in rats carrying a mutation in the SOD1 gene,one of the 40 genes associated with ALS development in humans.

While rats without the mutation completely recovered leg function four weeks after induced damage to the sciatic nerve, located in the leg, SOD1-mutated animals were unable to fully recover. These rats also lost function in the uninjured leg, likely as a consequence of sustained immune activation and more severe neurodegeneration.

The induced nerve damage mimics head injury and trauma in human patients, which could explain the higher prevalence of the disease among war veterans and professional athletes.

***

At ALS News Today, we hope these stories and our regular reporting throughout 2020 contribute to informing and improving the lives of everyone affected by ALS.

We wish all our readers a happy 2020.

Total Posts: 6

Ins holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Cincias e Tecnologias and Instituto Gulbenkian de Cincia. Ins currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.

Read the original here:
Top 10 ALS Stories of 2019 - ALS News Today

Posted in Cell Therapy | Comments Off on Top 10 ALS Stories of 2019 – ALS News Today

A First-in-Human Trial Offers Hope for CAR-T in Solid Tumors – Cancer Therapy Advisor

Posted: January 5, 2020 at 3:44 am

While chimeric antigen receptor T-cell (CAR-T) therapy has been making waves for the last few years as a novel treatment approach in cancer, the successes have remained mostly in the realm of blood cancers. This makes a first-in-human CAR-T clinical trial that targets a solid tumor growth receptor called MUC1* stand out. At the 34th Annual Meeting & Preconference Programs of the Society for Immunotherapy of Cancer, or SITC 2019, in November 2019, Minverva Biotechnologies shared an abstract offering some details behind this trial, which began in September 2019.1

Many clinical trials have tried to target the full-lengthMUC1 protein and have failed. The failures are likely due to the fact that MUC1is cleaved and released from the tumor surface, meaning any therapy that bindswith it goes too. When MUC1 is cleaved, however, the binding site for a crucialgrowth factor receptor that Minerva is calling MUC1* is revealed, said CynthiaBambdad, PhD, CEO of Minerva.

Leaving MUC1* exposed and unattended is like the pin beingpulled on the hand grenade, Dr Bamdad said. When a growth factor comes alongand binds to the MUC1* receptor, it causes the cancer cells to grow and becomeresistant to chemotherapy.

Minervas new investigational CAR-T therapy aims to swoop in and bind to the MUC1* receptor to block growth factors from accessing the MUC1 cleavage product. This binding and blocking action can, theoretically, stop a tumor from growing. The CAR-T therapy also aims to kill any mutant cancer cells in its vicinity and send out a call to the patients immune system to produce more like-minded CAR-T cells to shrink the tumor.

Its a very unique approach to MUC1, and thats why weemphasize that its different, said Matt Britz, head of business developmentat Minerva, referring to a line in the companys abstract that calls outprevious failed trials that looked only at full-length MUC1 and not the MUC1*receptor.

Up to now, CAR-T therapy has been so specifically successfulwith blood cancers because theyre malignancies of B cells, which CAR T-cellscan completely wipe out (it also can eliminate healthy B cells in the process,which can affect a patients ability to ward off infections). The patient mayget a sniffle more often, but is otherwise okay, Dr Bamdad remarked.

But this same approach doesnt work with solid tumors because they have no B-cell equivalent. Its been a challenge to find a solid tumor target that is not also present on healthy cells, which, if wiped out, could negatively impact a patients chances of survival.

Our approach is unique in that the CAR-T that we developedbinds to the part of MUC1* that is masked on healthy tissue, she said. TheCAR-T cells very selectively bind to and kill the tumor cells.

Dr Bamdad also said that MUC1*, which is expressedaberrantly in 95% of breast cancers, 83% of ovarian cancers, 78% of pancreaticcancers, and 71% of lung cancers, is the closest thing there is to a B-cellequivalent in solid tumors.

If this trial is successful, it will be a major step forward toward CAR-T cures for solid-tumor cancers, which make up 93% of all cancers, Dr Bamdad added.

Britz said that an obstacle in getting CAR-T therapy to gomainstream is that its still seen as being prohibitively expensive but heremains hopeful that as there are more successes in trials, there will be aparallel effort to bring the cost down. I think were in a paradigm shift inthe way that cancer is going to be treated, he said.

Reference

Bamdad C, Stewart A, Huang P, Smagghe B, Moe S, Swanson T,Jeon T, Page D, Mathavan K, Grant T, Herrup R. Poster presented at: the 34thAnnual Meeting & Preconference Programs (SITC 2019); November 610, 2019;National Harbor, MD. Abstract P150.

More:
A First-in-Human Trial Offers Hope for CAR-T in Solid Tumors - Cancer Therapy Advisor

Posted in Cell Therapy | Comments Off on A First-in-Human Trial Offers Hope for CAR-T in Solid Tumors – Cancer Therapy Advisor

Chronic PPI Use Linked to Declining Kidney Function Tops SPT Week in Review – Pharmacy Times

Posted: January 5, 2020 at 3:44 am

5. Mosunetuzumab Induces Complete Remissions in NHL After CAR T-Cell Therapy RelapseA novel, off-the-shelf bispecific antibody could serve as a new treatment option for patients with non-Hodgkin lymphoma who dont respond to CAR T-cell therapy. Read more.

4. Abemaciclib in Combination with Fulvestrant May Improve Care for Patients with HR+, HER2- Advanced Breast CancerAbemaciclib is a potent, oral cyclin-dependent kinase 4/6 inhibitor that has previously demonstrated statistically significant improvement in PFS and ORR in combination with endocrine therapy. Read more.

3. Microbes in Rectum Could be Key in Experimental HIV Vaccines Researchers aimed to understand whether microbes living in the rectum and vagina, sites of HIV transmission, interacted with experimental HIV vaccines similar to the HVTN 111 vaccine currently in early stage clinical trials in humans. Read more.

2. Tocilizumab Successful in Slowing Down Tuberculosis Bacillus Infection in Adult PatientsThe study led to insight on the process of tuberculosis bacillus infection as well as a potential drug treatment. Read more.

1. Chronic PPI Use Linked to Declining Kidney Function in Chronic Kidney DiseaseStudy findings presented at the American Society of Nephrologys Kidney Week 2019 suggest a link between chronic use of proton pump inhibitors and progression of kidney function decline in chronic kidney disease. Read more.

Read this article:
Chronic PPI Use Linked to Declining Kidney Function Tops SPT Week in Review - Pharmacy Times

Posted in Cell Therapy | Comments Off on Chronic PPI Use Linked to Declining Kidney Function Tops SPT Week in Review – Pharmacy Times

Allogene Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference – Yahoo Finance

Posted: January 5, 2020 at 3:44 am

SOUTH SAN FRANCISCO, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer, today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder, will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 8:30 a.m. Pacific Time. The event will be held in San Francisco at the Westin St. Francis.

A live audio webcast of the presentation will be available on the Investors section of Allogenes website, http://www.allogene.com. A replay of the webcast will be available on the website for approximately 30 days. Please connect to the companys website at least 15 minutes prior to the start of the presentation to ensure adequate time for any software download that may be required to listen to the webcast.

AboutAllogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, Allogene is developing a pipeline of off-the-shelf CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visitwww.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogenes expectations and actual results as discussed in greater detail in Allogenes filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-Q for the quarter ended September 30, 2019. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Allogene Media/Investor Contact:Christine CassianoChief Communications Officer(714) 552-0326Christine.Cassiano@allogene.com

Visit link:
Allogene Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference - Yahoo Finance

Posted in Cell Therapy | Comments Off on Allogene Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference – Yahoo Finance

What Does 2020 Have in Store for the Life Sciences? – BioSpace

Posted: January 5, 2020 at 3:44 am

With the books being closed on 2019, its time to prognosticate about what the next year will hold in the biotech and pharmaceutical industry. And, to paraphrase a famous song from the 1980s, grab a set of shades, because the future looks bright.

BioSpace spoke to leaders from various corners of the industry who provided their insights into what the coming year is likely to hold for their particular sphere. Below are predictions for three spheres within the industry for the coming year.

Oncology

Immuno-oncology has been one of the research cornerstones in cancer research and that will continue. However, in 2020, traditional targeted therapies will continue to be of importance. Stephen Gately, chief executive officer of TD2 (Translational Drug Development), an oncology-focused contract research organization, said there are still roles for traditional targeted therapeutics for specific indications. Following Mercks acquisition of ArQule, Inc. and its kinase inhibitor discovery and development programs for cancer treatment, predicted the industry might see a refocus on understanding cancer and how it can respond to different drugs. He said Merck would not have spent $2.7 billion for ArQules Phase II Brutons tyrosine kinase inhibitor ARQ 531 if there was not a potential upside for the therapy, particularly as a treatment for B-cell cancers. If trial protocols are well-established and there are stricter guidelines for patient selections, Gately said the use of certain inhibitors are vastly superior to immunotherapies in development.

When it comes to clinical trials, Gately predicted there could be a change in how those are organized. He said the goal for companies is to attempt to get their assets into trials as quickly as possible but noted there is a heated and competitive battle for trial sites. As companies attempt to elbow their way to the front of the line, Gately said it is possible that the industry will begin to see more opportunities for economic incentives used to convince the clinical trial sites to take up trials sooner. If that is established, Gately said it will become a game-changer.

Cell and Gene Therapies

This past year saw the approval of gene therapies that can address devastating diseases. And that is likely to continue in 2020. But, safety will still be paramount. Ena Cratsenburg, chief business officer of Ginkgo Bioworks, said over the course of the next year, we will see drug developers use synthetic biology to improve their ability to develop therapeutics with unprecedented levels of activity and control. In 2020, synbio companies will solidify their positions as key enablers in bringing the most innovative medicines to consumers, Cratsenburg said.

Mark Sawicki, chief commercial officer at Cryoport, developer of the first shippers certified for the delivery of human advanced therapies, said that as the cell and gene therapies continue to show their importance for treating new diseases, 2020 will usher in a record year for biologics license applications and marketing authorization applications. Sawicki suggested that over the course of the coming year, eight or nine companies will file such applications to gain regulatory approval of their products. In addition to the high number of filing companies, he suggested that there will be multiple new products launching with three or four generating revenues in 2020. By 2023, Sawicki predicts there will be at least 22 commercial launches in the space.

Jason Steiner, vice president of business development and strategy at gene editing company Synthego, said in 2020, the gap between the pace of innovation in the cell and gene therapy landscape and the infrastructure required for commercialization and deployment will continue to widen before it converges again.Steiner said the development of engineered cell therapies will continue to move toward non-viral approaches in order to boost engineering sophistication while decreasing the time and cost of traditional engineering. He added that manufacturing consideration of cell and gene therapies will continue to move farther upstream. They will be more tightly integrated with early development to avoid commercialization bottlenecks that are being caused by a rapid increase in the pace of development and regulatory approval cycles.

Real World Evidence

The importance of Real World Evidence (RWE) will continue to grow in 2020. Jane Reed, director of life sciences at U.K.-based Linguamatics, said the industry will continue to harness RWE in its drug development programs. RWE was not a topic of conversation in the industry 10 years ago, Reed said, but now there is significant value seen from what RWE brings to the table. RWE relates to the collection of information about a drugs safety and efficacy outside the structure of a clinical trial. The data can be collected from a variety of sources, including electronic health records, wearable devices, lab tests and more. The pharma industry will need to not only continue to collect the data, but learn to use it in a way that improves the outcomes of the patients it serves. Reed said the industry has to show they are listening to the patient community and be flexible. From there, the industry will need to feed that patient-driven data into drug discovery efforts. To boost the collection of RWE, Reed said the use of targeted social media research will also increase the amount of data that companies have at their fingertips. As companies within the pharmaceutical industry continue to dig into the depths of disease states, particularly those of rare diseases, Reed said the use of RWE will prove to be increasingly important.

Original post:
What Does 2020 Have in Store for the Life Sciences? - BioSpace

Posted in Cell Therapy | Comments Off on What Does 2020 Have in Store for the Life Sciences? – BioSpace

Global Musculoskeletal Disorder Stem Cell Therapy Market 2019 2024 Qualitative and Quantitative Assessment by Industry Analysis across the Value…

Posted: January 5, 2020 at 3:44 am

Global Musculoskeletal Disorder Stem Cell Therapy Market Growth (Status and Outlook) 2019-2024 Overview :

According to this study, over the next five years the Musculoskeletal Disorder Stem Cell Therapy market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024

A newly revealed market research study titledGlobal Musculoskeletal Disorder Stem Cell Therapy MarketbyMRInsights.biz, studies market insights, list of significant key professionals, threats of new competitors and alternate products. The report presents in-depth analysis along with competitive insights, segmentation, and the market size information. In addition, it exploresMusculoskeletal Disorder Stem Cell Therapymarket size, trends, share, growth, development plans, growth opportunity, cost structure and drivers analysis.One part of this report contains production in which analysis on the production, revenue, gross margin of its main manufacturers in different regions from 2014 to 2019 has been covered. It also makes a prediction of its production and consumption in coming 2019-2024. The report provides a detailed analysis by the categorization of the global market on the basis of regions.

DOWNLOAD FREE SAMPLE REPORT:https://www.mrinsights.biz/report-detail/177475/request-sample

Globally top leading manufacturers listed here: Osiris Therapeutics, NuVasive, Takeda (TiGenix), Medi-post,

Market region segmentation:

Furthermore, the SWOT analysis and strategies of each vendor are highlighted in the report which can be employed to create future opportunities.It sheds light on its applications, types, deployments, components, growths of this market. The research has also carried out analysis on upstream raw materials, equipment and downstream consumers. Next, it analyzes volume, utilization value, sale price, import and export in different regions from 2014 to 2019. On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, while for end use/application segment, this report focuses on the status and outlook for key applications.

The GlobalMusculoskeletal Disorder Stem Cell TherapyMarket Report Contains:

Next, the raw data collected through several sources has been processed using various mathematical and analytical tools and techniques in order to conclude the significant information related to future growth prediction trend for 2019 to 2024 time frame. At the end, research findings and conclusions specified in the report will help decision makers to take vital choices in the near future.

READ FULL REPORT:https://www.mrinsights.biz/report/global-musculoskeletal-disorder-stem-cell-therapy-market-growth-177475.html

There are 12 Chapters to deeply display the globalMusculoskeletal Disorder Stem Cell Therapymarket.

Chapter 1:Scope of the Report

Chapter 2:Executive Summary

Chapter 3:GlobalMusculoskeletal Disorder Stem Cell Therapyby Manufacturers

Chapter 4:Musculoskeletal Disorder Stem Cell Therapyby Regions

Chapter 5, 6, 7, 8 and 9:Americas,APAC,Europe,Middle East & Africa,Market Drivers, Challenges and Trends

Chapter 10 and 11:GlobalMusculoskeletal Disorder Stem Cell TherapyMarket Forecast,Key Players Analysis

Chapter 12 :Research Findings and Conclusion.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs.

Read the original here:
Global Musculoskeletal Disorder Stem Cell Therapy Market 2019 2024 Qualitative and Quantitative Assessment by Industry Analysis across the Value...

Posted in Cell Therapy | Comments Off on Global Musculoskeletal Disorder Stem Cell Therapy Market 2019 2024 Qualitative and Quantitative Assessment by Industry Analysis across the Value…

5 most popular innovation stories in Houston this week – InnovationMap

Posted: January 5, 2020 at 3:42 am

Thousands of startups call Houston home. According to the Greater Houston Partnership's data, the Houston area added 11,700 firms between 2013 to 2018. And, if you consider Crunchbase's tally, at the end of 2018, Houston had over 1,400 tech startups on the investment tracking website's radar.

This past year, InnovationMap featured profiles on dozens of these Houston startups from blockchain and software companies to startups with solutions in health care and oil and gas. Here are 10 that stood out throughout 2019.

Houston-based Topl can track almost anything using its blockchain technology. Getty Images

For Topl, 2019 was a year of laying the groundwork. In a January 2019 article on InnovationMap, Kim Raath, president of the Houston-based blockchain company, explained that Topl's mission originated out of the fact that 60 percent of the world lives on $10 a day and it's in the poorest regions of the world where it's the hardest to get funding for a new business.

Raath says that in her experience backpacking and volunteering all around the world she learned that banks are too overwhelmed to evaluate these potential businesses. Topl has created a technology where banks can easily generate a report on these entrepreneurs that evaluates and makes a loan or investment recommendation on the business.

"We are a generation that wants a story," she says. "We want an origin, and don't want to be fooled. And, because you might be able to reduce the cost by having this transparency, you might be able to bring down the cost on both sides."

Later that year, the company closed a 20 percent oversubscribed $700,000 seed round. With the money, Topl will be able to grow its platforms, provide better product features, and increase marketing efforts. Topl's customers are drawn to the technology because of the business efficiency the blockchain adds to their supply chain, but they are also excited about how having this technology differentiates them from their competition. Raath says she's interested in growing Topl's ability to do joint marketing campaigns with their customers.

Natalie Goodman founded Incentifind, which connects home builders and commercial developers with green incentives. Courtesy of Incentifind

When asked about the origin story of IncentiFind a Houston-based startup that connects real estate developers and home builders with green construction incentives founder Natalie Goodman doesn't mince words.

"We're a complete accident," Goodman tells InnovationMap in an interview in March. "I'm an architect. We didn't set out to have a startup."

IncentiFind's mission is to increase the amount of green developments and construction projects in the U.S. The company is equipped with a massive database of green incentives that are offered by utility, county, city, state and federal agencies. Many home builders or commercial developers don't take advantage of green incentives because they're simply not aware of them, Goodman says. Commercial developers can expect to spend around $1,500 with IncentiFind, while homeowners can expect to spend between $50 and $150.

Lazarus 3D is using 3D printing to help advance surgeons' skills. Photo via laz3d.com

It's pretty standard for surgeons in training to practice complicated surgeries on produce slicing bananas open and sewing grapes back together. But for a pair of Baylor College of Medicine-educated doctors, that didn't seem like sufficient prep for working with living bodies; fruit surgery was not fruitful enough. In 2014, Drs. Jacques Zaneveld and Smriti Agrawal Zaneveld founded Lazarus3D to build a better training model and layer by layer, they created models of abs and ribs and even hearts with a 3D printer.

"We adapted pre-existing 3D printing technology in a novel proprietary way that allows us to, overnight, build soft, silicone or hydrogel models of human anatomy," Jacques, who serves as CEO, tells InnovationMap in July. "They can be treated just like real tissue."

This year, the company grew to seven people and aims to expand even more to add to its sales and manufacturing teams. Having been funded mostly by friends and family investors, Lazarus3D plans enter its first equity round to raise $6 million, InnovationMap reported last summer.

Ryan Schwartz realized online dating was easier than finding a therapist. He created a tool to change that. Courtesy of Mental Health Match

Nearly five years ago, Ryan Schwartz sat in a coffee shop in crisis mode. His mother had just died suddenly and he was struggling to find an appropriate therapist. Across the table, his friend sat making a profile on a dating app. Quickly, her endeavor was complete and she was ready to swipe right, but Schwartz was still on the hunt for mental help.

"In two minutes she could have a profile matching her with a partner potentially for the rest of her life and I was sitting there for hours and hours trying to find a therapist," he told InnovationMap in June. "I thought it should be easier to find a therapist than a life partner. That's what sent me on my journey."

That journey reached a watershed last month when Schwartz launched Mental Health Match, a website designed to pair patients with their ideal therapist. The idea gained traction as Schwartz described it to people he met and found that many said they had experienced similar difficulties in finding the right practitioner for their needs.

Houston-based Grab makes it so you're waiting in one less line at the airport. Getty Images

Most airport lines are unavoidable, but a Houston startup has cut out at least some of those lines with its mobile ordering app. Houston-based software company Grab was founded by Mark Bergsrud in 2015, who worked in senior leadership roles for almost 20 years at Continental Airlines and then United Airlines, following the merger. For Bergsrud, Grab feels like another major mobile game changer the industry experienced.

"I spent many years thinking about the travel experience and how to make it better and faster," Bergsrud told InnovationMap in July. "This feels like how mobile check in felt. There was a problem customers didn't know they had check in wasn't that difficult anyway, but to be able to have that control, people love it."

Grab now has a presence in over 37 airports around the world, including Dallas and Austin though, ironically, not yet either of Houston's airports. Expansion is in the works for Grab, which closed a multimillion-dollar Series A round this year London-based Collinson Group was the sole contributor.

Houston-based NurseDash is the Uber of staffing nursing shifts in medical facilities. Photo via nursedash.com

Across the country, medical facilities are short on nurses. Agencies play a role in matchmaking nurses to open shifts, but agencies charge a high percentage for placement and lack transparency, says Andy Chen, former CFO for Nobilis Health Corporation. That's why he and Jakob Kohl created their app, NurseDash in 2017. The project manager for the app is in New York, but official headquarters in Houston's Galleria area, where a staff of five works with the team spread out around the world.

Since its debut, NurseDash has attracted 40 facilities in Houston, InnovationMap reported in May, including hospitals, surgery centers, and senior living, and about 400 nurses. Chen says he isn't sure just what to call his technology yet, but compares it to the ride hailing of Uber or Lyft and calls it "a virtual bulletin board."

Trevor Best, CEO of Syzygy Plasmonics, walked away from EarthX $100,000 richer. Photo via LinkedIn

A Houston technology company is doing something that, for many decades, wasn't thought to be possible. Syzygy Plasmonics is creating a hydrogen fuel cell technology that produces a cheaper source of energy that releases fewer carbon emissions. The hydrogen-fueled technology originated out of research done over two decades by two Rice University professors, Naomi Halas and Peter Nordlander.

Syzygy's technology, CEO Trevor Best told InnovationMap in August, is structured more like a battery than that of a combustion engine. Inside the technology, there are cells, lights, and mirrors making as bright as possible, which then spurs a reaction that creates energy. It has the potential to be cheaper it's made with cheaper materials and, of course, cleaner than traditional fueling technology with fewer carbon emissions released.

This new photocatalytic chemical reactor has the potential to shake up the industrial gas, chemical, and energy industries something that hasn't gone unnoticed by investors. Syzygy just closed a $5.8 million Series A round, and the funds will allow for Syzygy to continue to develop its technology and grow its team. Best tells InnovationMap that he expects to launch a full-size pilot by the end of 2020 and is already in talks with potential clients who are interested in the technology for industrial purposes.

Houston researchers are commercializing their organ 3D printing technology. Jordan Miller/Rice University

There may come a time when you or someone you love is in need of a new pair of lungs. Or perhaps it's a liver. It's not a scenario anyone dreams of, but thanks to Houston company Volumetric, you may never end up on a waiting list. Instead, that organ is made to order and 3D printed using a mix of medical plastics and human cells.

And this possibility isn't necessarily in the distant future. On the cover of the May 3 issue of the journal Science, is a contraption that looks a bit like a futuristic beehive. It's a working air sac complete with blood vessels, the beginnings of a technology that is perhaps only a decade from being implanted in humans. And it was crafted on a 3D printer in Jordan Miller's lab at Rice University. Miller and his bioengineering graduate student Bagrat Grigoryan are primed to profit from their inventions.

In 2018, they started Volumetric Inc., a company that sells both the hydrogel solutions used for printing organs like theirs and the printers themselves. Touring Miller's lab in the Houston Medical Center is a visual timeline of his team's progress designing printers. The version being manufactured is a slick little number, small enough to fit under chemical exhaust hoods, but fitted with everything necessary to print living tissues. It's made and sold in cooperation with CellInk, a larger bioprinting company.

"Our technology is based on projection," Miller told InnovationMap in May. Specifically, it's stereolithography, a type of 3D printing that produces the finished product layer-by-layer. Shining colored light of the right intensity turns the polymers into a solid gel.

Voyager, a Houston SaaS company, has received fresh funds to develop its bulk shipping software. Tom Fisk/Pexels

Houston software startup Voyager is making waves in its quest to improve efficiency and stem billions of dollars in losses in the maritime bulk-shipping business. Now, it's got some fresh capital to help it achieve that mission.

InnovationMap reported in August that Houston-based Voyager revealed it secured $1.5 million in seed funding from four investors from around the world: Austin-based ATX Venture Partners, Houston- and California-based Blue Bear Capital, New York City-based GreenHawk Capital, and Oman-based Phaze Ventures. Previous investors include Boulder, Colorado-based Techstars and Spring-based Knightsgate Ventures.

With its software-as-a-service offering, Voyager aims to modernize the workflows of operators in the maritime bulk-commodities industry. The company says its technology will become more vital as autonomous shipping and internet- and Internet of Things-enabled cargo vessels grow in popularity. Voyager's technology enables all communication tied to a shipment to be handled via its web dashboard and app, essentially creating a one-stop shop for people who need to track messages about maritime bulk shipments.

"With Voyager, what it allows companies to do is essentially have all of those counter parties working together in a shared environment to manage the voyage together entirely email free," Matthew Costello, CEO, tells InnovationMap in December.

Educated as an engineer, Chris DuPont has stepped outside his professional comfort zone to generate funding for his Houston-based startup, Galen Data Inc. DuPont's pool of technical contacts in Houston is "wide and deep," he says, but his pool of financial contacts had been shallow.

Overcoming obstacles in Houston's business waters, DuPont has raised two rounds of angel funding he declines to say how much that have enabled Galen Data to develop and market its cloud-based platform for connecting medical devices to the internet, including pacemakers and glucose monitors. DuPont is the startup's co-founder and CEO.

Galen Data's patent-pending technology lets medical device manufacturers tailor the cloud-based software to their unique needs. DuPont says his company's software is geared toward medical devices that are outside, not inside, hospitals and other healthcare facilities. He declines to divulge how many customers the startup has.

Hatched within Houston-based Tietronix Software Inc., DuPont's previous employer, Galen Data launched in 2016 but didn't roll out its first product until 2018. Galen Data's emergence comes as the market for internet-connected mobile health apps keeps growing. One forecast envisions the global space for mobile health exceeding $94 billion by 2023.

"We want to be at the forefront of that technology curve," DuPont tells InnovationMap in May. "We might be six months early, we might be a year early, but it's starting to happen."

See the original post here:
5 most popular innovation stories in Houston this week - InnovationMap

Posted in Colorado Stem Cells | Comments Off on 5 most popular innovation stories in Houston this week – InnovationMap

Top 10 Parkinson’s Stories of 2019 – Parkinson’s News Today

Posted: January 5, 2020 at 3:41 am

Parkinsons News Today keeps you up-to-date with research into Parkinsons disease as it emerges. We brought you daily coverage of experiments into the basic biology of Parkinsons, results of clinical and pre-clinical trials, and key findings from Parkinsons research around the globe.

We look forward to bringing more such news to those with Parkinsons, their family, friends and caregivers throughout 2020.

Here are our 10 most-read stories of 2019, with a short summary of what makes each one relevant to the Parkinsons community.

No. 10 Active Form of Vitamin B12 Found to Prevent Neurodegeneration in Study of Animal Models

A study found that an active form of the vitamin B12 called AdoCbl can ease the effects of dopamine loss that occurs in Parkinsons disease. Using cell lines and several animal models, researchers showed that by reducing LRRK2 enzyme activity, AdoCbl limits the death of dopamine-producing nerve cells, thereby preventing the appearance of symptoms associated with neurodegeneration. Overactivity of LRRK2 is linked to the development of a hereditary form of Parkinsons. AdoCbl is already an FDA-approved compound, and could be used as a basis to develop new therapies to combat hereditary Parkinsons associated with pathogenic variants of the LRRK2 enzyme, according to Iban Ubarretxena, director of theBiofisika Institute and a study co-author.

No. 9 Onstryv Now Approved for Parkinsons Patients in Canada

Canadian Parkinsons disease patients now have access to Onstryv (safinamide), also known as Xadago. Onstryv increases the amount of active dopamine in the brain by both preventing the enzyme that breaks dopamine down from doing so, and by blocking that enzyme from entering cells. Other available treatments cause debilitating fluctuations between normal motor function (called on episodes) and poorer motor function (off periods) as their effects ebb and flow. Four placebo-controlled Phase 3 trials showed that the combination of Onstryv and levodopa led to more on and fewer off periods, and improved motor function in patients. The approval of [Onstryv] in Canada is a step forward for patients who need new treatment options for Parkinsons disease, said Roberto Tascione, CEO of Zambon, one of the companies involved in commercializing this medication.

Xadago was approvedby theU.S. Food and Drug Administration in March 2017 to improvemotor functionin Parkinsons patients who experience off periods while on treatment withlevodopaand/or Lodosyn (carbidopa).

No. 8 Plant Antioxidant Seen to Aid Mitochondria and Ease Motor Problems in Early Parkinsons Study

A pre-clinical study conducted in China showed that alpha-arbutin, an antioxidant found in plants such as the blueberry, might restore mitochondrial function in nerve cells and ease the motor disabilities associated with Parkinsons disease. Treatment with alpha-arbutin partially restored mitochondrial function in nerve cells undergoing oxidative stress (mitochondria act as a cells power house). It also restored these cells ability to remove toxic waste products. Feeding alpha-arbutin to flies carrying a mutated gene known to trigger Parkinsons significantly eased several Parkinsons-like symptoms. Naturally derived-antioxidants might serve as a new class of therapeutic options for [Parkinsons disease], the researchers wrote.

No. 7 Stem Cell Transplants Could Significantly Improve Parkinsons Treatment, Study Suggests

Replacing damaged cells in Parkinsons disease with dopamine-producing stem cells could easemotor symptoms and reduce or eliminate the need for pharmaceutical medicines. As current disease therapies lose their efficacy over time, stem cell therapy might revolutionize Parkinsons treatment, its researchers said.A single surgery could potentially provide a transplant that would last throughout a patients lifespan, reducing or altogether avoiding the need for dopamine-based medications, said Claire Henchcliffe MD, PhD, and Malin Parmar, PhD, co-authors of a study on the benefits of stem cell therapy. However, there are several biological, practical, and commercial hurdles that need circumventing for this to become a routine therapy, according to the editors of theJournal ofParkinsons Disease.

No. 6 Bacteria in Gut Can Promote Parkinsons by Altering Brains Immune Reactions, Study Says

A study found evidence of interaction between the brain and the gut in Parkinsons, in which Gram-negative bacterial infections in the gut trigger an immune response that damages nerve cells. Gut microorganisms are known to communicate with the central nervous system, andstudies suggest that harmful proteins related to Parkinsons may spread to the brain from the gut.Scientists at theUniversit de Montral showed that Gram-negative bacteria, particularly those related to gut infections, triggered an immune response in cells taken from mice. They then showed that mice bred without thePINK1 gene (making them resistant to Parkinsons-like symptoms), when infected with these bacteria, displayed an immune response that led to such symptoms. Mutations in the PINK1 gene cause damage to the mitochondria in brain cells, and are linked to early onsethereditary Parkinsons. The work provides evidence that intestinal infection acts as a triggering event in Parkinsons, andhighlighted the relevance of a gut-brain connection in this disease.

No. 5 Next 20 Years Expected to Bring Message of Hope to Parkinsons Patients, Review Study Finds

By reviewing the past 20 years of research into Parkinsons disease, two scientists see a strong potential for breakthroughs in how this disease is approached over the next 20 years. The review cited developments in better animal models, greater understanding of molecular mechanisms and risk factors, and advances in available and potential therapies as reasons for hope. Among highlights of many advances listed are: 1) the adaptation of existing medicines used in other diseases to treat Parkinsons (drug repurposing); 2) targeting non-motor features such as cognition, speech and balance difficulties that often precede motor symptoms; 3) the use of nanoparticles to block the formation of toxic alpha-synuclein clusters; and, 4) emerging evidence of a link between harmful gut bacteria and brain inflammation. The review also stressed the importance of future trials to test combination therapies.

No. 4 Physical Activity, Coffee, Moderate Alcohol Consumption Protect Against Disease Progression, Study Reports

Good news for lovers of sports, caffeine, and happy hours all of these things, in moderation, may help slow the onset of symptoms of Parkinsons disease. Although how exactly these lifestyle factors affect disease progression remains poorly understood, they correlate strongly with better patient outcomes. Conversely, smoking, heavy drinking and no consumption of alcohol at all were linked to considerably worse outcomes. The study, published in the journalMovement Disorders, needs to be replicated to strengthen the usefulness of its findings. Nonetheless, the work suggests that multiple lifestyle factors potentially modify the rate of symptom progression, its researchers wrote.

No. 3 Dietary Supplement Eases Parkinsons Symptoms, Improves Dopamine Function, Study Shows

The antioxidant dietary supplement N-acetyl-cysteine (NAC) may improve dopamine function and ease Parkinsons disease symptoms, according to one study. The body uses NAC to produce an antioxidant called glutathione (GSH), which it uses to prevent the oxidative stress that leads to cell death. Damage due to oxidative stress within dopamine-producing neurons is a key clinical feature of Parkinsons. A trial (NCT02445651), conducted by researchers atThomas Jefferson University in Philadelphia, showed that NAC supplementation significantly eased both motor andnon-motor symptoms among 42 Parkinsons patients (21 men and 21 women). These results need to be confirmed in larger and placebo-controlled studies, but offer an encouraging start to a potential low-cost therapy.

No. 2 Low Vitamin D Levels Linked to Added Falls, More Sleep Problems, Depression, Study Shows

Low levels of vitamin D were associated with more falls, and greater problems withinsomnia, anxiety, anddepressionin people withParkinsons disease, according to a study by Chinese researchers. Vitamin D deficiency has often been seen in people with Parkinsons, but its relationship to the disease remains controversial. This study, by researchers at theSecond Affiliated Hospital of Soochow UniversityandSoochow University, is one of the few to measure both motor and non-motor outcomes. By conducting detailed clinical evaluations in 182 Parkinsons patients, as well as 185 healthy controls, the group found that low levels of vitamin D were more common in Parkinsons patients than in healthy people, and that vitamin D supplements may ease the diseases nonmotor symptoms.

No. 1 Oral Magnesium Compound Able to Reach Brain Seen to Slow Motor Decline, Neuronal Loss in Early Study

Our years most-read story was of an early stage studyreporting that a type of oral magnesium could enter the brain and ease motor symptoms and nerve cell loss in a mouse model of Parkinsons disease. Mice given magnesium-L-threonate, which can cross the blood-brain barrier (a semipermeable membrane that protects the brain from the outside environment) reduced the loss of dopamine-producing neurons, slowed the decline in motor function, and limited the oxidative stress that is associated with Parkinsons. It is important to note that while magnesium-L-threonate provided therapeutic benefits, magnesium sulfate the first choice as a clinical magnesium supplement did not. [T]he combination of [magnesium] with an agent that promotes its transportation to the brain is essential for the neuroprotection of this element, the studys scientists wrote.

***

AtParkinsons News Today we hope these stories and our reporting throughout 2020 help to better inform and improve the lives of everyone affected by Parkinsons.

We wish all our readers a happy 2020.

Total Posts: 208

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

View original post here:
Top 10 Parkinson's Stories of 2019 - Parkinson's News Today

Posted in Stem Cell Treatments | Comments Off on Top 10 Parkinson’s Stories of 2019 – Parkinson’s News Today

Page 1,201«..1020..1,2001,2011,2021,203..1,2101,220..»